ArticleEBioMedicine2018
A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Bioprofiling and vaccine development for Zika virus.Science China. Life sciences · 2025Review
- Review
- An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024Review
- Article
- Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71.Virologica Sinica · 2024Article
- A review on Zika vaccine development.Pathogens and disease · 2024Review
- Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate.Scientific reports · 2023Article
- A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model.PloS one · 2022Article
- Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine.Vaccines · 2021Article
- Current Progress in the Development of Zika Virus Vaccines.Vaccines · 2021Review
- Zika virus-an update on the current efforts for vaccine development.Human vaccines & immunotherapeutics · 2021Article
- Self-Assembling Nanovaccine Enhances Protective Efficacy Against CSFV in Pigs.Frontiers in immunology · 2021Article
- Identifying optimal capsid duplication length for the stability of reporter flaviviruses.Emerging microbes & infections · 2020Article
- Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection.EBioMedicine · 2020Article
- Evaluation in Swine of a Recombinant African Swine Fever Virus Lacking the MGF-360-1L Gene.Viruses · 2020Article
- Disruption of Zika Virus xrRNA1-Dependent sfRNA1 Production Results in Tissue-Specific Attenuated Viral Replication.Viruses · 2020Article
- Reverse genetic approaches for the development of Zika vaccines and therapeutics.Current opinion in virology · 2020Review
- A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Using recombination-dependent lethal mutations to stabilize reporter flaviviruses for rapid serodiagnosis and drug discovery.EBioMedicine · 2020Article
- The Cellular Impact of the ZIKA Virus on Male Reproductive Tract Immunology and Physiology.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundVaccines are the most effective means to fight and eradicate infectious diseases. Live-attenuated vaccines (LAV) usually have the advantages of single dose, rapid onset of immunity, and durable protection. DNA vaccines have the advantages of chemical stability, ease of production, and no cold chain requirement. The ability to combine the strengths of LAV and DNA vaccines may transform future vaccine development by eliminating cold chain and cell culture with the potential for adventitious agents.
methodsA DNA-launched LAV was developed for ZIKV virus (ZIKV), a pathogen that recently caused a global public health emergency. The cDNA copy of a ZIKV LAV genome was engineered into a DNA plasmid. The DNA-LAV plasmid was delivered into mice using a clinically proven device TriGrid™ to launch the replication of LAV.
findingsA single-dose immunization as low as 0.5 μg of DNA-LAV plasmid conferred 100% seroconversion in A129 mice. All seroconverted mice developed sterilizing immunity, as indicated by no detectable infectious viruses and no increase of neutralizing antibody titers after ZIKV challenge. The immunization also elicited robust T cell responses. In pregnant mice, the DNA-LAV vaccination fully protected against ZIKV-induced disease and maternal-to-fetal transmission. High levels of neutralizing activities were detected in fetal serum, indicating maternal-to-fetal humoral transfer. In male mice, a single-dose vaccination completely prevented testis infection, injury, and oligospermia.
interpretationThe remarkable simplicity and potency of ZIKV DNA-LAV warrant further development of this vaccine candidate. The DNA-LAV approach may serve as a universal vaccine platform for other plus-sense RNA viruses. FUND: National Institute of Health, Kleberg Foundation, Centers for Disease Control and Prevention, University of Texas Medical Branch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.